Rapport Therapeutics, Inc. Common Stock
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a RAPP research report →
Range $47 – $91
Price Chart
About the company
Rapport Therapeutics, Inc. functions as a clinical-phase biopharmaceutical enterprise, concentrating its efforts on discovering and developing innovative small-molecule therapeutics for individuals living with central nervous system (CNS) disorders. Its flagship product candidate, RAP-219, is an experimental small molecule precisely designed to inhibit TARPy8-containing AMPARs with exceptional potency (picomolar affinity).
- CEO
- Abraham N. Ceesay
- IPO
- 2024
- Employees
- 84
- HQ
- Boston, MA, US
Get TickerSpark's AI analysis on RAPP
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $1.11B
- P/E
- -7.31
- PEG
- 0.39
- P/S
- 55.56
- P/B
- 2.83
- EV/EBITDA
- -6.59
- Div Yield
- 0.00%
- Gross Margin
- 100.00%
- Op Margin
- -838.08%
- Net Margin
- -752.35%
- ROE
- -34.00%
- ROIC
- -41.84%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $0+0.0%
- Op Income
- $-125,099,000
- Net Income
- $-111,483,000-42.4%
- EPS
- $-2.86-33.6%
- OCF Growth
- -34.9%
- FCF Growth
- -31.0%
- 52W High
- $52.93
- 52W Low
- $22.06
- 50D MA
- $29.85
- 200D MA
- $35.51
- Beta
- 1.03
- RSI (14)
- 37
- Avg Volume
- 790.62K
No earnings-call transcripts are available for RAPP yet.
- Free Float
- 47.8%
- Shares Outstanding
- 47.98M
- Float Shares
- 22.95M
of shares held by institutions
166 13F filers
Buy/sell ratio 3.67. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Fmr LLC | 7.20M | ▲ 23.76K |
| Trv Gp V, LLC | 6.28M | 0 |
| Arch Venture Management, LLC | 3.73M | 0 |
| Goldman Sachs Group Inc | 2.97M | ▲ 63.35K |
| Blackrock, Inc. | 2.88M | ▲ 181.48K |
| Capital International Investors | 2.65M | ▼ 268.32K |
| Cormorant Asset Management, LP | 2.46M | ▼ 200.00K |
| Sofinnova Investments, Inc. | 1.90M | 0 |
| Vanguard Group Inc | 1.82M | ▲ 191.22K |
| Johnson & Johnson | 1.78M | 0 |
| Polar Capital Holdings PLC | 1.60M | ▼ 4.93K |
| Vanguard Capital Management LLC | 1.58M | ▲ 233.48K |
Held by 228 ETFs
Biggest fund positions in RAPP by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Oct 30, 26 | Third Rock Ventures V, L.P. | other | 238,095 |
| Oct 30, 26 | Third Rock Ventures V, L.P. | other | 1,190,476 |
| Oct 28, 26 | HEALY JAMES | buy | 952,380 |
| Oct 28, 26 | HEALY JAMES | buy | 6,933 |
| Oct 28, 26 | HEALY JAMES | buy | 6,395 |
| Oct 28, 26 | HEALY JAMES | buy | 3,772 |
| Oct 21, 26 | Ceesay Abraham | sell | 2,210 |
| Oct 23, 26 | Sanchez Ramiro | buy | 3,600 |
| Oct 22, 26 | Silva Paul M | buy | 3,680 |
| Oct 22, 26 | Young Wendy B. | buy | 3,789 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our RAPP coverage
Recent articles, reports, and earnings notes.
No research on RAPP yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate RAPP report →Insider Buying Signals: 3 Healthcare Stocks to Watch
investorplace.com · Nov 11
Rapport Therapeutics Reports Third Quarter 2026 Financials and Provides Business Update
globenewswire.com · Nov 4
Rapport Therapeutics to Participate in Upcoming Investor Conferences
globenewswire.com · Nov 3
Rapport Announces Closing of Public Offerings of Common Stock and Pre-Funded Warrants and Convertible Notes, Including Full Exercise of Underwriters' Options to Purchase Additional Shares and Notes, as well as Concurrent Private Placement
globenewswire.com · Nov 2
Rapport Announces Pricing of Underwritten Offerings of Common Stock and Pre-Funded Warrants and Convertible Notes and Concurrent Private Placement
globenewswire.com · Oct 28
Rapport Announces Proposed Public Offerings of Common Stock and Convertible Notes as well as Concurrent Private Placement
globenewswire.com · Oct 27
Insider Selling: Rapport Therapeutics (NASDAQ:RAPP) CEO Sells $64,443.60 in Stock
defenseworld.net · Oct 26
Rapport Therapeutics' RAP-219 Hits Phase II Goals in Bipolar Mania Trial
marketbeat.com · Oct 25
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.